China Healthcare Weekly (Oct.20)-Investment Returns on Weight Loss/AD,GLP-1 Gene Therapy,AIM Vaccine
⬇ $AIM Vaccine(06660)$ - Weight loss and Alzheimer's disease (AD) would generate different investment returns.We're conservative about the outlook of GLP-1 gene therapy.We consider AIM Vaccine risky and recommend staying away Continue reading on Smartkarma:- https://www.smartkarma.com/insights/china-healthcare-weekly-oct-20-investment-returns-on-weight-loss-ad-glp-1-gene-therapy-aim-vaccine?utm_source=tiger_community By Xinyao (Criss) Wang, Insight Provider on Smartkarma:- https://www.smartkarma.com/profiles/xinyao-criss-wang?utm_source=tiger_community On AIM Vaccine (06660):- https://www.smartkarma.com/entities/aim-vaccine-co-ltd?utm_source=tiger_community
China Healthcare Weekly (Mar.31) - 8th National VBP Result, Chinese Patent Medicine VBP, AIM Vaccine
⬇ $AIM Vaccine(06660)$ - The 8th national VBP released results.The impact of VBP on companies is decreasing. Chinese patent medicine VBP is coming, but some companies can cope well.AIM doesn’t have long-term investment value. Continue reading on Smartkarma:- https://www.smartkarma.com/insights/china-healthcare-weekly-mar-31-8th-national-vbp-result-chinese-patent-medicine-vbp-aim-vaccine?utm_source=tiger_community By Xinyao (Criss) Wang, Insight Provider on Smartkarma:- https://www.smartkarma.com/profiles/xinyao-criss-wang?utm_source=tiger_community On AIM Vaccine (06660):- https://www.smartkarma.com/entities/aim-vaccine-co-ltd?utm_source=tiger_community